Targets for immunotherapy of liver cancer.


Drug development in hepatocellular carcinoma (HCC) has been characterised by many failures in the past. Despite good rationales and promising phase II data, many phase III trials failed. Immunotherapy represents an alternative treatment approach that has been successful in many different cancer types. As an inflammation induced cancer, HCC represents a very… (More)
DOI: 10.1016/j.jhep.2017.09.007


2 Figures and Tables

Slides referencing similar topics